Durvalumab/tremelimumab/nab-paclitaxel/gemcitabine regimen well tolerated in metastatic PDAC Feb. 7, 2018
STAT3 shown as potential therapeutic target for gastroenteropancreatic neuroendocrine tumors Feb. 7, 2018
AstraZeneca's application to expand Tagrisso indication in Japan granted priority review Feb. 7, 2018